High efficacy of combined rituximab and gemcitabine on Epstein-Barr virus-associated human B-cell lymphoma obtained after Hodgkin's xenograft in immunodeficient mice

Anti-Cancer Drugs

Volumn 17, Issue 6, 2006, Pages 685-695

  Decaudin, Didier ^a   Marszak, Fanny Baran ^c   Couturier, Jérôme ^a   Mathiot, Claire ^a   Martin, Antoine ^c   Némati, Fariba ^a   Lantz, Olivier ^a   Santo, James Di ^b   Arnaud, Philippe ^a   Bordier, Vincent ^a   Vincent Salomon, Anne ^a   Poupon, Marie France ^a  

^a INSTITUT CURIE   (France)

^b INSERM   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

Epstein Barr virus; Gemcitabine; Hodgkin's disease; Posttransplant lymphoproliferative disease; Rituximab

Indexed keywords

CD15 ANTIGEN; CD30 ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN; GEMCITABINE; IMMUNOGLOBULIN HEAVY CHAIN; RITUXIMAB; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER GENETICS; CANCER GRAFT; CANCER INHIBITION; CHROMOSOME 12; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CYTOGENETICS; DRUG EFFICACY; EPSTEIN BARR VIRUS; FEMALE; GENE REARRANGEMENT; GENETIC ANALYSIS; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE BIOPSY; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; VIRUS EXPRESSION; XENOGRAFT;

ADULT; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD22; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; DEOXYCYTIDINE; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPH NODES; LYMPHOMA, B-CELL; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL, DIFFUSE; MALE; MICE; MICE, KNOCKOUT; MICE, SCID; NUCLEIC ACID HYBRIDIZATION; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 33747598464     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000215061.78189.4e     Document Type: Article

References (54)

1. Loren AW, Porter DL, Stadtmauer EA, Tsai DE. Post-transplant lymphoproliferative disorder: a review. Bone Marrow Transplant 2003; 31:145-155.
2. Benkerrou M, Durandy A, Fischer A. Therapy for transplant-related lymphoproliferative diseases. Hematol Oncol Clin North Am 1993; 7:467-475.
3. Benkerrou M, Jais JP, Leblond V, Durandy A, Sutton L, Bordigoni P, et al. Anti-B cell monoclonal antibody treatment of severe posttransplant B-lymphoproliferative disorder: prognostic factors and long-term outcome. Blood 1998; 92:3137-3147.
4. Tsai DE, Hardy CL, Tomaszewski JE, Kotloff RM, Oltoff KM, Somer BG, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001; 71:1076-1088.
5. Swinnen LJ, Mullen GM, Carr TJ, Costanzo MR, Fisher RI. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 1995; 86:3333-3340.
6. Mamzer-Bruneel MF, Lome C, Morelon E, Levy V, Bourquelot P, Jacobs F, et al. Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: a report of 16 cases observed in a single center. J Clin Oncol 2000; 18:3622-3632.
7. Faye A, Van Den Abeele T, Peuchmaur M, Matthieu-Boue A, Vilmer E. Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders. Lancet 1998; 352:1285.
8. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Ann Oncol 2000; 11:113-116.
9. Ganne V, Siddiqi N, Kamaplath B, Chang CC, Cohen EP, Bresnahan BA, et al. Humanized anti-CD20 monoclonal antibody (Rituximab) treatment for post-transplant lymphoproliferative disorder. Clin Transplant 2003; 17:417-422.
10. Papadopoulos EB, Ladanyi M, Emanuel D, Mackinnon S, Boulad F, Carabasi MH, et al. Infusion of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Eng J Med 1994; 330:1185-1191.
11. Rooney CM, Smith CA, Cy Ng, Loftin SK, Sixbey JW, Gan Y, et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood 1998; 92:1549-1555.
12. Nalesnik MA, Rao AS, Zeevi A, Fung JJ, Pham S, Furukawa H, et al. Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients. Transplant Proc 1997; 29:1905-1906.
13. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235-242.
14. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-1423.
15. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Clin Cancer Res 2003; 9:3945S-3952S.
16. Harris NL, Jaffe ES, Diébold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17:3835-3849.
17. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339:1506-1514.
18. Diehl V, Sieber M, Ruffer U, Lathan B, Hasenclever D, Pfreundschuh M, et al. BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group. Ann Oncol 1997; 8:143-148.
19. Colucci F, Soudais C, Rosmaraki E, Vanes L, Tybulewicz VL, Di Santo JP. Dissecting NK cell development using a novel alymphoid mouse model: investigating the role of the c-abl proto-oncogene in murine NK cell differentiation. J Immunol 1999; 162:2761-2765.
20. Mitelman F, editor. ISCN (1995) An International system for human cytogenetic nomenclature. Basel: Karger; 1995.
21. Aubin J, Davi F, Nguyen-Salomon F, Leboeuf D, Debert C, Taher M, et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 1995; 9:471-479.
22. Camilleri-Broet S, Davi F, Feuillard J, Seilhean D, Michiels JF, Brousset P, et al. AIDS-related primary brain lymphomas: histopathologic and immunohistochemical study of 51 cases. The French Study Group for HIV-Associated Tumors. Hum Pathol 1997; 28:367-374.
23. Kallioniemi OP, Kallioniemi A, Piper J, Isola J, Waldman FM, Gray JW, et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 1994; 10:231-243.
24. Poupon M-F, Arvelo F, Goguel AF, Bourgeois Y, Jacrot M, Hanania N. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst 1993; 85:2023-2029.
25. Nakamine H, Masih AS, Okano M, Taguchi Y, Pirruccello SJ, Davis JR, et al. Characterization of clonality of Epstein-Barr virus induced human B lymphoproliferative disease in mice with severe combined immunodeficiency. Am J Pathol 1993; 142:139-147.
26. Locker J, Nalesnik M. Molecular genetic analysis of lymphoid tumors arising after organ transplantation. Am J Pathol 1989; 153:977-987.
27. Rowe M, Young LS, Crocker J, Stokes H, Henderson S, Rickinson AB. Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man. J Exp Med 1991; 173:147-158.
28. Meggetto F, Muller C, Henry S, Selves J, Mariame B, Brousset P, et al. Epstein-Barr virus (EBV)-associated lymphoproliferations in severe combined immunodeficient mice transplanted with Hodgkin's disease lymph nodes: implication of EBV-positive bystander B lymphocytes rather than EBV-infected Reed-Sternberg cells. Blood 1996; 87:2435-2442.
29. Grillo-Lopez AJ. Rituximab: an insider's historical perspective. Semin Oncol 2000; 6:9-16.
30. Maloney DG, Smith B, Appelbaum F. The anti-tumor effect of monoclonal anti-CD20 antibody (mAb) therapy includes direct antiproliferative activity and induction of apoptosis in CD20 positive non Hodgkin's lymphoma (NHL) cell lines [abstract 2535]. Blood 1996; 88:637a.
31. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Semin Oncol 2002; 29(1 Suppl 2):2-9.
32. Faye A, Quartier P, Reguerre Y, Lutz P, Carret AS, Dehee A, et al. Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children. Br J Haematol 2001; 115:112-118.
33. Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation. Lancet 1999; 354:1698-1699.
34. Yedibela S, Reck T, Niedobitek G, Gramatzki M, Repp R, Hohenberger W, et al. Anti-CD20 monoclonal antibody treatment of Epstein-Barr virus-induced intrahepatic lymphoproliferative disorder following liver transplantation. Transpl Int 2003; 16:197-201.
35. Ghobrial IM, Habermann TM, Ristow KM, Ansell SM, Macon W, Geyer SM, et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46:191-196.
36. Savoldo B, Rooney CM, Quiros-Tejeira RE, Caldwell Y, Wagner HJ, Lee T, et al. Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative disease. Am J Transplant 2005; 5:566-572.
37. Garcia VD, Bonamigo Filho JL, Neumann J, Fogliatto L, Geiger AM, Garcia CD, et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003; 16:202-206.
38. Jenkins D, DiFrancesco L, Chaudhry A, Morris D, Gluck S, Jones A, et al. Successful treatment of post-transplant lymphoproliferative disorder in autologous blood stem cell transplant recipient. Bone Marrow Transplant 2002; 30:321-326.
39. Zompi S, Tulliez M, Conti F, Leblond V, Gaulard P, Blanche P, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with clonal lymphoproliferative disorders after orthotopic liver transplantations: a report of three cases. J Hepatol 2000; 32:521-527.
40. Dotti G, Rambaldi A, Fiocchi R, Motta T, Torre G, Viero P, et al. Anti-CD20 antibody (rituximab) administration in patients with late occurring lymphomas after solid organ transplant. Haematologica 2001; 86:618-623.
41. Skoda-Smith S, Douglas VK, Mehta P, Graham-Pole J, Wingard JR. Treatment of post-transplant lymphoproliferative disease with induction chemotherapy followed by haploidentical peripheral blood stem cell transplantation and rituximab. Bone Marrow Transplant 2001; 27:329-332.
42. Heinemann V. Gemcitabine in metastatic breast cancer. Exp Rev Anticancer Ther 2005; 5:429-443.
43. Zinzani PL, Baliva G, Magagnoli M, Bendandi M, Modugno G, Gherlinzoni F, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol 2000; 18:2603-2606.
44. Sallah S, Wan JY, Nguyen NP. Treatment of refractory T-cell malignancies using gemcitabine. Br J Haematol 2001; 113:185-187.
45. Santoro A, Bredenfeld H, Devizzi L, Tesch H, Bonfante V, Viviani S, et al. Gemcitabine in the treatment of refractory Hodgkin's disease: results of a multicenter phase II study. J Clin Oncol 2000; 18:2615-2619.
46. Zinzani PL, Bendandi M, Stefoni V, Albertini P, Gherlinzoni F, Tani M, et al. Value of gemcitabine treatment in heavily pretreated Hodgkin's disease patients. Haematologica 2000; 85:926-929.
47. Venkatesh H, Di Bella N, Flynn TP, Vellek MJ, Boehm KA, Asmar L. Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma. Clin Lymphoma 2004; 5:110-115.
48. Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17:3786-3792.
49. Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT, et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000; 11:595-597.
50. Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 113:772-778.
51. Ganjoo KN, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, et al. A phase II of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin's lymphoma: a Hoosier Oncology Group Study. Am J Clin Oncol 2005; 28:169-172.
52. Larson BJ, Waples JM, Pusateri A, Mendenhall NP, Lynch Jr. JW. A phase II of gemcitabine in patients with relapsed or refractory low-grade non-Hodgkin's lymphoma. Am J Clin Oncol 2005; 28:165-168.
53. Wenger C, Stern M, Herrmann R, Rochlitz Ch, Pless M. Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non Hodgkin's lymphoma? Leuk Lymphoma 2005; 46:71-75.
54. Emmanouilides C, Jazirehi AR, Bonavida B. Rituximab-mediated sensitization of B-non-Hodgkin's lymphoma (NHL) to cytotoxicity induced by paclitaxel, gemcitabine, and vinorelbine. Cancer Biother Radiopharm 2002; 17:621-630.